Dashboard
Manage Tickers

GNPXGenprex, Inc.

Nasdaq genprex.com


$ 0.66 $ 0.02 (3.13 %)    

Tuesday, 20-Aug-2024 15:53:00 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 0.66
$ 0.63
$ 0.65 x 400
-- x --
$ 0.59 - $ 0.66
$ 0.56 - $ 22.41
340,898
na
1.71M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-01-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-21-2023 06-30-2023 10-Q
6 05-22-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-26-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-14-2020 03-31-2020 10-Q
19 03-30-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
21 08-13-2019 06-30-2019 10-Q
22 05-15-2019 03-31-2019 10-Q
23 04-01-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 04-17-2018 12-31-2017 10-K
28 11-27-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

genprex-cmo-reports-clincal-study-updates-from-acclaim-1-and-acclaim-3-phase-12-clinical-trials-in-lung-cancer
Genprex CMO Reports Clincal Study Updates ...
08/15/2024 13:37:47

genprex-decides-to-cease-enrollment-in-the-acclaim-2-clinical-trial-due-to-difficulties-in-recruiting-patients-citing-competition-from-numerous-other-trials-limiting-the-acclaim-1-trial-to-a-single-cohort-due-to-resource-prioritization-reducing-the-potential-breadth-of-the-study
Genprex Decides To Cease Enrollment In The...
08/14/2024 13:46:51

genprex-reports-clinical-study-updates-from-acclaim-1-and-acclaim-3-phase-12-clinical-trials-in-lung-cancer
Genprex Reports Clinical Study Updates Fro...
08/14/2024 13:28:12

Demonstrates Prolonged Progression Free Survival of Two Patients in Acclaim-1 and Partial Remission from Maintenance Therapy in...

crude-oil-down-2-paysafe-shares-surge-after-q2-results
Crude Oil Down 2%; Paysafe Shares Surge Af...
08/13/2024 18:30:30

sp-500-gains-1-home-depot-earnings-top-views
S&P 500 Gains 1%; Home Depot Earnings Top ...
08/13/2024 16:15:58

nasdaq-surges-200-points-us-producer-prices-increase-01-in-july
Nasdaq Surges 200 Points; US Producer Pric...
08/13/2024 13:54:30

genprex-granted-patent-in-singapore-for-reqorsa-gene-therapy-in-combination-with-pd-1-antibodies-through-2037
Genprex Granted Patent In Singapore For Re...
08/13/2024 12:33:13

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors

genprex-shares-are-trading-higher-after-the-company-provided-2024-updates
Genprex shares are trading higher after th...
06/27/2024 13:10:30

genprex-issues-letter-and-provides-2024-update-reached-multiple-clinical-development-milestones-in-2024-patient-treatment-continues-in-three-lung-cancer-clinical-trials
Genprex Issues Letter And Provides 2024 Up...
06/27/2024 12:35:17

https://www.genprex.com/downloads/2024-genprex-stockholder-letter.pdf 

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
05/31/2024 16:31:09

hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Genp...
05/17/2024 12:18:05

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Genp...
05/15/2024 15:28:23

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

genprex-administers-first-dose-in-acclaim-3-clinical-study-of-reqorsa-immunogene-therapy-combined-with-tecentriq-to-treat-small-cell-lung-cancer
Genprex Administers First Dose In Acclaim-...
05/14/2024 12:32:35

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on deve...

genprex-appoints-jose-a-moreno-toscano-as-chairman-of-the-board-of-directors
Genprex Appoints Jose A. Moreno Toscano As...
05/13/2024 12:39:57

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
04/26/2024 12:06:32

genprex-earlier-reported-preclinical-data-for-reqorsa-immunogene-therapy-and-nprl2-gene-therapy-for-lung-cancer
Genprex Earlier Reported Preclinical Data ...
04/09/2024 13:41:31

Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer T...

hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Genp...
04/04/2024 10:33:39

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

genprex-expands-clinical-trial-sites-for-acclaim-3-clinical-study-of-reqorsa-therapy-in-combination-with-tecentriq-for-small-cell-lung-cancer
Genprex Expands Clinical Trial Sites For A...
04/03/2024 12:32:28

 Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices       ...

hc-wainwright--co-reiterates-buy-on-genprex-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Genp...
04/03/2024 10:23:53

HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.

genprex-publishes-preclinical-data-with-nprl2-gene-therapy-using-oncoprex-delivery-system
Genprex Publishes Preclinical Data With NP...
04/02/2024 12:34:36

NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanize...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION